Abstract: The present disclosure relates to a coding test device and a coding test method. The coding test device according to one embodiment includes a problem provider for providing a test problem including an initial condition to a user terminal, a code receiver for receiving first algorithm code corresponding to the initial condition from the user terminal, and an additional condition provider for determining whether a predetermined passing condition for the first algorithm code is satisfied and providing an additional condition related to the initial condition to the user terminal based on the result of determination for the first algorithm code.

Abstract: The present disclosure relates to a coding test device and a coding test method. The coding test device according to one embodiment includes a problem provider for providing a test problem including an initial condition to a user terminal, a code receiver for receiving first algorithm code corresponding to the initial condition from the user terminal, and an additional condition provider for determining whether a predetermined passing condition for the first algorithm code is satisfied and providing an additional condition related to the initial condition to the user terminal based on the result of determination for the first algorithm code.

Abstract: The present invention relates to a chimeric antigen receptor and immune cells expressing same and, more specifically, to a chimeric antigen receptor and immune cells, preferably T cells, expressing same, the chimeric antigen receptor comprising: an anti-mesothelin antibody or a fragment thereof; a signal peptide of CD8a; a hinge of CD28 or CD8a; a transmembrane domain of CD28 or CD8a; and an intracellular signaling domain comprising intracellular signaling region sequences of CD28, 4-1BB, and CD3?. The chimeric antigen receptor and T cells expressing same according to the present invention can be effectively used for cancer treatment since the immune cells exhibit excellent anticancer activity.